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III. General introduction and aims 
 
 High quality pilot clinical studies occupy an important role in the development of 
novel medications and also in gathering information of diseases with yet unknown or debated 
etiological background. Especially in such cases when relatively rare or orphan diseases are in 
the scope of research, since patients suffering from these illnesses can hardly hope for large 
pharmaceutical companies (controlled by the rules of economy and competition) to develop 
medications for their needs. Although pilot clinical studies have the disadvantage of including 
only smaller amount of patients, with the meta-analysis or systematic review of several 
publications good, comprehensive evidence can be gathered on a certain topic. 
 It has to be stated, that a well organized and planned study requires thorough 
preparation and also the collaboration of different healthcare professionals (medical doctors, 
pharmacists, nurses, microbiologists, statisticians, analytical etc.). Each profession gives an 
added value to the work and is essential for the successful completion of the study.  
 As a pharmacist I would like to highlight some important topics regarding a pilot 
clinical study I had a chance to participate in. I hope that my work gives a good example of 
the diversified professional challenges that clinical pharmacists have to face. 
In 2006 a double blind, randomized pilot clinical study was planned and launched to 
assess the efficacy of long term intranasal antifungal treatment in patients suffering from 
chronic rhinosinusitis with nasal polyposis (CRSwNP), because it has been hypothesized that 
fungal cells in the mucus exacerbate adverse immune response that result in the formation of 
polyps. Several studies have been published on the issue and controversial results can be 
found on the effectiveness of antifungal treatment. Before this well prepared study was 
started, the question of stability arose regarding the study medications. After the completion 
of a three month stability test further questions had to be faced regarding the adequate 
analysis of amphotericin B (AmB) solutions. Instructive and useful experience was gained 
while problems of microbiologic and instrumental analytical possibilities were solved. 
In my thesis I will aim to introduce a complex pharmaceutical view regarding a pilot 
clinical study organized by the Department of Otorhinolaryngology and Head and Neck 
Surgery in cooperation with Department of Pharmaceutics and University Pharmacy of the 
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University of Pécs in 2006. During the preparation phase we had to face several 
pharmaceutically important questions. 
The aims of my thesis are to: 
 evaluate earlier clinical studies regarding to the antifungal treatment for 
chronic rhinosinusitis; 
 assess the efficacy of long-term AmB treatment in patients with CRSwNP and 
also to describe the compliance of patients in the study; 
 discuss pharmaceutically important topics regarding the study sample, such as 
the preparation of clinical samples, optimal dosage form, proper concentration 
of the active ingredient, storage and stability; 
 introduce the different chemical and microbiological analytical methods for the 
measurement of AmB and summarize our work in the improvement of these 
techniques. 
Since such diversified topics and fields of research are included in my work, in the 
interest of transparency I divided the thesis into two sections. In the first clinical section the 
etiology and the therapy of CRSwNP is discussed along with the detailed presentation of the 
double blind pilot study of Pécs and the results of our compliance measurements. In the 
second analytical section the challenging problem of the analysis of AmB and the questions 
regarding a stability testing are introduced. Also the applied chemical and biological methods 
are presented and compared. 
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IV. Section One: Clinical part 
 
A. Chronic Rhinosinusitis with Nasal Polyposis 
 
Chronic rhinosinusitis (CRS) is an inflammatory disease of the nasal and paranasal 
sinus mucosa that has existed for more than 3 months, with typical leading symptoms such as 
nasal obstruction, thick mucopurulent nasal discharge, a reduction/loss of the ability to smell, 
facial pressure and/or pain, in some cases accompanied by an extreme degree of nasal 
polyposis (NP) (1). As concomitant minor symptoms, CRS patients may complain of 
headaches, fever, halitosis, fatigue, dental pain and ear fullness.  
 
1. Epidemiology of the disease 
 
Current medical research suggests that CRS can be referred to as a multifactorial 
disease, which may be associated with asthma, cystic fibrosis, primary ciliary dyskinesia, 
aspirin intolerance and allergy (2). Around 4% of the population suffers from a compromised 
quality of life in consequence of the disease (3). It affects mainly adult patients older than 20, 
with at least 2:1 male to female ratio. One third of patients with NP have asthma, but polyps 
are found in only 7 % of asthmatics (4). Significant medical resource expenditures and global 
economic costs accompany CRS (5). 
 
2. Etiology and the theories of polyp development 
 
The etiology and pathogenesis of CRS are neither largely unknown. One of the most 
popular theories, which is a subject of intensive research, postulates that the causal factors are 
morphological variations on the lateral wall of the nasal cavity (3); other hypotheses include 
the biofilm theory (6) and the role of superantigens (7). The basic standard treatment is 
surgical intervention and the use of corticosteroids. It should be emphasized that even the 
most modern antibiotics are effective only during the acute exacerbations of CRS, making a 
bacterial etiology doubtful. The fact that antiallergic medication results in a symptomatic 
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improvement merely in the event of a proved concomitant allergy suggests that an IgE-
mediated allergy is not an etiological factor of CRS (8). 
Figure 1. Categorization of rhinosinusitis and current classification of fungal 
rhinosinusitis (9). 
 
The role of fungal organisms in the development of some rare forms of CRS has long 
been known. Allergic fungal rhinosinusitis (AFRS) was first described by Katzenstein et al. in 
1980 (10). DeShazo and Swain (11) and later on Bent and Kuhn (12) proposed the criteria of 
this previously rarely diagnosed disease. Ponikau et al. recently developed new mucus-
collecting and culturing methods with which they were able to demonstrate the presence of 
mucin containing hyphae and clusters of degenerating eosinophils (Charcot-Leyden crystals) 
referring to allergy in 96% of CRS patients with polyposis undergoing endoscopic sinus 
surgery (13). See Appendix A for the list of cultured fungi from patients and healthy adults. 
With the diagnostic criteria of DeShazo and Swain, the previously rarely diagnosed AFRS 
was seen in 93% of their patients. To their surprise, with this new method they cultured at 
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least two fungal species individually in the nasal mucus of a control group consisting of 14 
healthy adults, but without detection of the presence of an IgE-mediated type I 
hypersensitivity reaction. The number of organisms recovered from patients and healthy 
control subjects are summarized in Appendix A. In the opinion of Ponikau et al. “allergic 
mucin” exists independently from an IgE-mediated type I hypersensitivity reaction. For this 
reason, they proposed a change in the terminology: they prefer the term “eosinophilic mucin” 
(EM) instead of “allergic mucin”, and suggest that “allergic fungal rhinosinusitis” be changed 
to “eosinophilic fungal rhinosinusitis”. Thus, the eosinophilic granulocytes within the nasal 
mucus of CRS patients do not play a part in allergic reactions, but are transitory components 
of the nasal secretion. After destroying the hyphae, they fall apart and the major basic protein 
released from them exerts an extremely toxic effect on nasal mucosa (14). As a consequence 
of secondary superinfection of the nasal mucosa via an epithelial lesion, biofilm colonization 
and the appearance of superantigens CRS may develop. All these facts indicate the 
multifactorial nature of the disease. 
Figure 2. Computer tomography scans (axial view on the left, side view on the 
right) of a patient with intensive polyposis obliterating the ethmoid- , frontal , maxillary 
and sphenoid sinuses and the nasal cavities. 
 
Pant et al. recently proved the absence of fungi in the EM of some CRS patients (15). 
They also demonstrated the similarity in clinicopathologic features between EM CRS 
subgroups despite the occurrence of positive fungal cultures and hypersensitivity against 
fungi. Their observations indicated that the presence of EM always reflects a more severe 
grade of CRS than that in its absence. Erbek et al. showed that the grade of eosinophilia is 
Nasal polyps 
Nasal polyps 
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more influential as regards the severity of CRS than the presence of a positive fungal culture 
(16). 
If the fungal theory holds true, it seems obvious that, through a reduction of the 
amount of antigen, or its total eradication, thereby influencing the triggers of CRS, the 
symptoms of the patients can be relieved. Accordingly the treatment of CRS patients with 
intranasal lavage or a spray containing AmB would be beneficial.  
 
B. Review and evaluation of earlier publications 
 
1. Introduction of studies 
 
During the past 7 years, seven clinical studies have been published in which 
experience with local antifungal treatment regimes in CRS was discussed (13, 17, 18, 19, 20, 
21, 22). The controversial characteristics of these studies are summarized in Table 1. Only 
three of the papers were based on double-blind, placebo-controlled studies (18, 19, 22)
,
 and of 
these three studies only one was multicentre (22), making the interpretation of the results 
rather difficult. One of the studies excluded patients with AFRS completely (19). In some of 
the studies, the number of recruited patients was extremely low (20, 18). The treatment period 
ranged between 4 and 80 weeks, and the form of drug/placebo application also varied since 
nasal lavage, nasal spray and nasal inhalation was used. The concentration and the daily 
amount of AmB recommended also differed in these studies. The conditions of drug storage 
and checking the stability of the AmB solutions was completely ignored in most of these 
studies. Due to the fact that the patient compliance was examined in only one study (22), it is 
extremely difficult to draw conclusions concerning the effectiveness or ineffectiveness of 
AmB treatment. 
Recently a multicenter randomized controlled study has been published evaluating the 
effect of topical AmB on inflammatory markers in samples of nasal lavage fluid, from 
patients with CRS with or without NP. The authors had to conclude that AmB had no 
significant effect on the level of any of the tested pro-inflammatory cytokines, chemokines 
and growth factors (23). 
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Table 1. Summary of clinical studies of amphotericin B treatment of Chronic Rhinosinusits with Nasal Polyposis 
Authors 
A. Ricchetti 
et al. 
J. U. Ponikau 
et al. 
J. U. Ponikau 
et al. 
M. Weschta 
et al. 
A. Helbling 
et al. 
C. Corradini 
et al. 
F. A. Ebbens 
et al. 
Year 2002 2002 2005 2004 2006 2006 2006 
Journal J Laryng & Otol 
J Allergy Clin 
Immunol 
J Allergy Clin 
Immunol 
J Allergy Clin 
Immunol 
J Laryng & Otol 
J Investig Allergol 
Clin Immunol 
J Allergy Clin 
Immunol 
Type of study open open 
double-blinded, 
placebo-controlled 
double-blinded, 
placebo-controlled 
open open 
multicentre, 
double-blinded, 
placebo controlled 
Number of patients 
involved 
74 51 30 78 21 89 116 
Amphotericin B 
treatment 
74 51 10 28 21 39 59 
Length of treatment 4 weeks 12 weeks 24 weeks 8 weeks 12 weeks 80 weeks 12 weeks 
Application lavage lavage lavage spray spray inhalation lavage 
Amphotericin B 
concentration 
0,1 mg/ml 0,1 mg/ml 0,25 mg/ml 3 mg/ml 10 mg/ml 3,33 mg/ml 0,1 mg/ml 
Daily amount of 
Amphotericin B 
8 mg 8 mg 20 mg 4,8 mg 3 mg 0,8 and 0,5 mg 10 mg 
Daily application 2x20-20 ml 2x20-20 ml 2x20-20 ml 4x0,2-0,2 ml 3x0,1-0,1 ml 1x0,24/0,16 ml 2x25-25 ml 
Storage mentioned no no no refrigerator refrigerator no refrigerator 
Stability mentioned no no no no no no yes 
Compliance mentioned no no no no no no yes 
Final outcome Effective Effective Effective Ineffective Ineffective Effective Ineffective 
11 
 
2. Controversial and ignored factors in previous studies 
 
There are several factors which need to be evaluated and discussed in detail. These are 
the following: 
 Dosage form/application method of sprays and nasal lavages 
 Preparation of spray solutions and concentration of the active substance 
 Role of added glucose in the solutions 
 Length of therapy 
 Compliance of patients 
 Storage and stability of study medication 
In the previously published studies different dosage forms were used. In case of nasal 
lavages/irrigation the sinuses are washed with 20-25 ml solution. It is arguable, whether the 
washing effect of the solution could in itself be beneficial in CRS (24), in this way potentially 
influencing therapeutic outcome. 
In general if the concentration of the antifungal substance is higher in the solutions 
than the minimal inhibitory concentration (MIC) for a specific yeast or filamentous fungi, 
presumably it would be effective. It should be taken into consideration that because of ciliary 
activity in the nose, the active ingredient would be diluted. The antifungal spectrum of AmB 
is particularly broad and the great majority of fungi are susceptible to a very low 
concentration, generally at a MIC of < 0,5 μg/ml (25). In previous studies the concentration of 
solutions ranged from 0,1 to 10,0 mg/ml, in all cases exceeding MIC by 2000-20000 fold. 
The substance AmB is insoluble in water. Although it can be dissolved in dimethyl 
sulfoxide (DMSO) such solutions cannot be used as nasal sprays since the solvent would 
irritate the nasal mucosa. Thus previous AmB sprays and washes for clinical studies were 
made from commercially available preparations such as Fungizone and Amphomoronal. 
These are colloidal suspensions with bad stability parameters and according to the 
manufacturer’s instructions the water base solutions can’t be diluted with saline, because 
monovalent ions would cause the precipitation in the colloidal system. Because it has been 
documented that during intravenous administration any precipitation increases the toxicity, 
only 5% glucose solution is considered to be sufficient for the dilution of AmB colloidal 
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preparations (26). Presumably for this reason one author used glucose infusions for the 
dilution of nasal spray solutions (19). In our judgment glucose could adversely influence the 
antifungal effect of medications since it is well known that glucose accelerates the growth of 
fungi and act as an energy source for most medically important fungi. 
It should be noted that according to Meltzer (27) the antifungal treatment should last 
for at least 6 months and only three publications fulfil this criteria. 
The former authors have not referred to any published stability tests of AmB solutions, 
thus the constant antifungal activity of the test medications between visits was questionable in 
each case. Although AmB solutions are considered to be relatively unstable, only three 
authors have referred to optimal storage temperature. 
More than 450 patients were included in these studies, but the attitude of the patients 
and their adherence to the medication has not been reported. 
In an attempt to clarify the situation, we conducted a double-blind, prospective, 
randomized, placebo-controlled clinical study. This differed from the previous ones in that, 
the active drug or placebo was administered postoperatively in the form of a nasal spray. We 
preferred the use of a nasal spray to nasal lavage because of the well-known, favourable effect 
of hypertonic saline solution on the symptoms of CRS (28, 29). As a result of nasal lavage, 
the mucociliary activity improves, the degree of mucous membrane oedema and the 
concentrations of inflammatory mediators decrease and the inspissated mucous can be cleared 
mechanically (30). 
It is important from the aspect of compliance that application of a nasal spray is more 
convenient for patients than either nasal lavage or inhalation. A significant amount of nasal 
lavage is frequently swallowed, questioning its therapeutic effectiveness in the depths of 
polyp-filled sinuses, especially if it is used preoperatively. The application of AmB is 
favoured by the facts, that the drug is not/or poorly absorbed through the gastrointestinal tract, 
and it is highly effective (90%) against the majority of fungi cultured from the sinonasal tract 
(see cultured fungi in Appendix A). In our study the concentration of the drug was 5 mg/ml, 
which is at least 1600-5000 times higher than the MIC. We considered it reasonable to apply 
the AmB in the postoperative period, when the drug could pass easily and effectively into the 
EM-free sinuses. 
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C. Results of the randomized, double blind placebo control study at Pécs 
1. Patients and methods 
 
In a double-blind, randomized, placebo-controlled study, patients received AmB (A 
group) or placebo (B group) nasal sprays for 12 months after polypectomy with functional 
endoscopic sinus surgery (FESS). Our aim was to determine whether any difference could be 
observed between the two groups in the rates of recurrence of nasal polyposis, in the 
symptoms, in the quality of life or in the endoscopic findings. The protocol of the study was 
approved (no. 2005/11.25/2632) by the Regional Ethics Committee of the University of Pécs 
Medical Centre. All the patients received concomitant nasal steroid sprays and were allowed 
to use their regular medication. The study protocol is presented in Figure 3. Thirty-three 
patients with CRSwNP were recruited from among the patients presenting at our clinic for 
endoscopic sinus surgery between November 2005 and October 2006. Thirty patients 
completed the study; 3 patients were excluded (group A: 2, group B: 1) because of 
noncompliant behaviour. The patient demographics are shown in Table 2. 
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Figure 3. Study protocol of the double blind placebo control clinical study 
 
 
 
Table 2. Demographic data on patients participating in the clinical study 
 
 Amphotericin B 
group 
(n = 14) 
Placebo 
group 
(n = 16) 
Mean age (SD) 51 (10.32) 56 (9.81) 
Male/female 9/5 10/6 
Asthma (n) 3 5 
ASA intolerance (n) 1 1 
Allergy  
(general) (n) 
6 8 
Allergy 
(antifungal) (n) 
0 0 
Smoking (n) 3 3 
Previous 
procedures 
  
FESS (1 op) 3 3 
FESS (2 op) 0 1 
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The diagnosis for CRS was set up according to the criteria laid down by the “EAACI 
position paper on rhinosinusitis and nasal polyps, executive summary” (3). The diagnosis was 
confirmed by the presence of symptoms that has existed for 3 months and the swelling of the 
nasal mucosa by 5 mm in at least 2 sinuses according to the CT scans and endoscopic 
observations. Exclusion criteria are listed in Table 3. 
Table 3. Criteria for exclusion from the clinical study 
 
Known hypersensitivity to amphotericin B 
Pregnancy or lactation 
Age <18 years 
Suspicion of allergic fungal rhinosinusitis 
Mental disease, cystic fibrosis 
Osteoporosis, chronic liver or renal disease 
Immune-compromised state (HIV, transplantation, diabetes) 
Acute upper airway infection (within a week) 
Complication of CRS (e.g., abscess) 
Acute bacterial exacerbation of CRS (acute pain, 
pressure feeling, high temperature, mucopurulent discharge) 
Orbital or intracranial complication of CRS 
Antibiotic and/or antihistamine therapy within 3 weeks 
Application of oral steroid within 3 weeks 
Systemic antifungal therapy within 1 week 
 
 Patients were assigned to the two treatment arms by simple randomization. The AmB 
and placebo nasal sprays were compounded in the Central Clinical Pharmacy of Pécs. The 
two solutions were indistinguishable by colour, smell or taste. The active spray made from 
Fungizone (Bristol-Myers Squibb, Epernon, France) contained 5 mg/ml AmB, 4.1 mg/ml 
sodium deoxycholate and 20.2 mg/ml sodium phosphate in sterile distilled water, while the 
placebo was an aqueous 0.2 μg/ml acriflavin chloride solution. The antifungal activity of 
acriflavin chloride was assessed earlier and proved to be ineffective against the tested fungus 
strain (C. albicans) even at hundred fold higher concentrations. The sprays were 
manufactured under aseptic conditions and were measured out in brown, light-rejecting glass 
containers with dosing spray caps. The patients received 7 spray containers of 3.3 ml 
solutions monthly and were instructed to apply 2 times 2 doses (100 μl) daily into each 
nostril, i.e. the total daily dose of AmB was 4 mg/day. We earlier tested the stability of the 
solutions at 4 °C: the 5 mg/ml AmB solutions proved stable for 30 days (31)(see also Chapter 
VI.C.).  
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Primary outcome variables 
 Modified Lund-Mackay CT score 
The scoring system as modified by Juniper (32, 33) was used to evaluate the computer 
tomography (CT) scans of the patients prior to endoscopic sinus surgery and also after the 12-
month treatment period (see Appendix B1.).  
Secondary outcome variables 
Sinonasal Assessment Questionnaire (SNAQ-11) 
Compared with similar tools (the Sino Nasal Outcome Test 20, SNOT-20; or the General 
Nasal Patient Inventory, GNPI) the 11-item SNAQ-11 (34) allows a more adequate evaluation 
of the main symptoms of CRS (e. g. nasal congestion or loss of the sense of smell), without a 
deep analysis of the nonspecific symptoms (such as a feeling of aural pressure). The 
questionnaire is shown in Appendix B2. The questionnaires were completed by all the 
patients both before surgery and one year later, at the end of the study period. 
Quality of life test 
The questionnaires were filled out prior to surgery and after 12 months (Appendix B3.). The 
patients answered the 6 questions on a 7 grade scale (35); the maximum score was 36. 
Endoscopic assessment 
Following nasal mucus membrane congestion all the patients were graded preoperatively and 
one year later, at the end of the therapy, according to the scoring system of Malm (36). All 
grading was performed by the same MD. The scores ranged from 0 (no polyp) to 3 (total 
obstruction). 
Statistical analysis 
 For the analysis of the primary outcome measure (the CT score), the SNAQ-11 and the 
quality of life scores, independent sample t-tests were used. The applicability of this was 
checked with the Levene test, and the normality of the variables was demonstrated with 
Kolgomorov-Smirnov test. The procession and evaluation of the data were performed with 
the SPSS 14.0 for Windows (SPSS Inc., Chicago, Illinois, USA). The results are expressed as 
medians ± interquartile ranges. 
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2. Results 
 
 Fourteen of the 16 patients in group A, and 16 of the 17 patients in group B completed 
the study. 
Modified Lund-Mackay CT score 
During the evaluation of the preoperative and postoperative CT scans, we observed high 
standard deviation in the scores without any relevant improvement. Though a slight 
improvement was seen in the placebo group (Figure 4.), the comparison of the two patient 
groups did not indicate a significant change (p=0.052). 
Figure 4. Preoperative and postoperative CT scores (modified Lund-Mackay test) in the 
two groups of patients. Means are indicated by horizontal lines, the rectangle denotes 
the mean ±25 % values. 
 
 
Sinonasal symptom score (SNAQ-11) 
A relevant improvement in the symptoms was observed in both medication groups (Figure 5.) 
but a statistically significant difference was not observed when the changes in the two groups 
were compared (p > 0.1). 
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Figure 5. Preoperative and postoperative symptomatic scores in the two groups of 
patients 
 
Quality of life test 
A definite improvement was observed in both groups after 12 months (Figure 6.), but the 
rates of improvement in the two groups did not differ statistically significantly (p > 0.1). 
Overall, the changes in the sinonasal symptoms and quality of life scores correlated with each 
other but a statistically significant change was not observed in the rate of improvement 
between the two groups. 
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Figure 6. Preoperative and 12 month postoperative quality of life test data in the two 
groups of patients 
 
Endoscopic assessment 
Table 4. shows the endoscopic status of the patients at the beginning and at the end of the 
study, based on the system of Malm. Although the study population was relatively small, it 
can be clearly seen that there were more patients in the placebo group whose endoscopic 
status did not change. On the other hand, 1, 2 and 3-level changes were observed in more 
cases in the AmB group. 
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Table 4. Preoperative and 12-month postoperative endoscopic stages in the two groups 
of patients 
 
Endoscopic stages Amphotericin B 
group (n) 
Placebo 
group (n) Preoperative Postoperative 
Stage III. Stage III. 0 0 
Stage III. Stage II. 1 2 
Stage III. Stage I. 2 2 
Stage III. Stage 0. 4 2 
Stage II. Stage II. 1 1 
Stage II. Stage I. 2 2 
Stage II. Stage 0. 2 2 
Stage I. Stage I. 0 4 
Stage I. Stage 0. 1 1 
Total 14 16 
Change in state n (%) n (%) 
0 1 (8) 5 (31) 
1 5 (36) 5 (31) 
2 4 (28) 4 (25) 
3 4 (28) 2 (13) 
Total 14 (100) 16 (100) 
 
Side-effects 
Headache, sleep disorders, nasal congestion, fatigue, phlegm/catarrh in the back of the 
throat and cough are common symptoms of CRS, and thus they can’t be considered side-
effects of the therapy. Short-term nasal burning was reported by 6 patients in the AmB group, 
and only 1 patient mentioned dryness of the nasal mucus and bleeding in the placebo group. 
The therapy did not have to be interrupted because of side-effects in any of the cases. 
Our evaluation of the preoperative and postoperative CT scans in the AmB group did 
not reveal an improvement in the scores; the data were scattered significantly. However, an 
improvement was noted in the placebo group. The comparison of the extents of change in the 
two groups did not indicate a significant difference (p=0.052). In this respect, mention should 
be made of the well-known clinical experience that the symptomatic recovery following 
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endoscopic sinus surgery does not correlate significantly with the extent of improvement seen 
on the CT scans (37, 38). 
Our patients displayed marked improvements in the sinus complaints by the end of the 
1-year course of treatment in both groups, though without a significant difference in the 
extent of change in the two groups. During the evaluation of the results, it should be borne in 
mind that AmB also exerts a direct toxic effect on the epithelial cells of nasal polyps, but does 
not damage the integrity of turbinate epithelial cells. Many authors explain the successful 
AmB treatment of nasal polyposis through this effect (39). It should be noted that no polyp 
tissue was present in our study population at the beginning of antifungal treatment which rules 
out any possible anti-polyp tissue effect of AmB. During the surgical procedures, the mucus 
in the sinuses, potentially containing fungal antigens, was thoroughly eliminated. These two 
facts may have contributed to the final outcome that the two groups did not exhibit a 
significant difference as concerns the changes in the symptoms even after 1 year. A 
significant difference was not observed in the quality of life test either; the explanation of this 
might be similar to that described in connection with the evaluation of the sinus complaints. 
The assessment of the preoperative and the 12-month postoperative findings clearly 
shows that 1, 2 or 3-stage changes occurred more often in the AmB group, while an 
unchanged endoscopic finding was observed more frequently in the placebo group. However, 
in view of the relatively small number of patients, caution is advisable in the interpretation of 
this finding. Nonetheless, it is a fact that the endoscopic finding did not correlate with the 
changes observed in either the primary or the secondary outcome measures. 
 
D. Evaluation of patient adherence and adverse events 
1. Significance of compliance measurement 
 
As mentioned before there are several factors that need to be taken into consideration 
when evaluating the outcome of different publications. Thus throughout the planning and the 
organizing phase of our study we were focusing on such factors which could have an 
influential effect. The knowledge of patient adherence (the extent to which the patient’s actual 
history of drug administration corresponds to the prescribed regimen) is important both in 
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medical research and in clinical practice. The results of clinical trials cannot be interpreted 
realistically without adherence information (40). The aim of our measurements was to assess 
patient adherence and to identify non-adherent patients during a 12-month double-blind 
clinical trial relating to the safety and efficacy of an AmB nasal spray self-administered for 
the treatment of CRSwNP. Because there is no gold standard for the measurement of 
adherence/compliance, the combination of two indirect methods (self-reporting and recording 
of the amount of medication administered) furnished better information concerning the 
attitudes of the patients and the factors influencing adherence. Assessments were made of 
how the adherence changed during the 12-month period, which factors influenced the 
attitudes of the patients and what adverse events were reported. The correlation between the 
adverse events and the adherence, and the comparability of the two adherence measurement 
methods were considered. 
 
2. Methods 
 
Participants 
Thirty-three patients were recruited into the clinical study by the Department of 
Otorhinolaryngology, Head and Neck Surgery. Each patient was required to read and sign a 
form of informed consent and the study was approved by the Regional Research Ethic 
Committee of the University of Pécs Medical Centre. The patients ranged in age from 33 to 
76 years (mean = 53,1 years); 50,0 % of them were male; the duration of their education 
ranged from 8 to 17 years (mean = 14,5); the  number of scheduled medications in addition to 
the AmB nasal spray ranged from 0 to 8 (mean = 2,4). Thirty of the 33 patients completed the 
12-month treatment period, they were requested to complete the Brief Medication 
Questionnaire (BMQ) and 27 did so at the last visit (response rate 90%). 
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Measures 
Two indirect methods were used for the measurement of adherence: (a) recording of 
the amount of medication self-administered and (b) self-reporting by the patient via the 
Hungarian translated version of the standardized BMQ revised in 2003 (41). The amount of 
medication self-administered was recorded monthly by measuring the residual fluid in the 
spray containers to an accuracy of 0,1 ml (1 dose or unit = 0,1 ml). The cut-off point applied 
to define adherent patients was 80 %. Adherence was calculated according to the following: 
 
The accuracy of the BMQ was assessed earlier by using electronic monitoring with the 
Medication Event Monitoring System (Apres, Apria Healthcare, Fremont, California). The 
BMQ was translated into Hungarian by the authors and the wording of the instrument was 
edited for use with nasal sprays and adjusted to our study. Of the 16 questions in the BMQ 
three questions regarding the medication name, the reason for taking the medication and the 
amount paid were omitted since the sprays had codes, were the only medication involved in 
the study and were provided to the participating patients free of charge. Four questions were 
added to identify the use of other medications or nasal sprays and to ask how participants used 
the sprays throughout the whole 12-month trial period. The answers to these questions, not 
being in the original version, were not integrated into the Adherence Risk Scale (ARS) at the 
evaluation of the BMQ. 
The Regimen Screen contained questions regarding the past week of treatment. The 
patients received a score of “1” if their answers to the questions indicated potential non-
adherence and “0” if their report indicated adherence. The Belief Screen measured two beliefs 
that can be linked to non-adherence: doubts about the efficacy of the treatment, and unwanted 
side-effects or bothersome features. The patients received a score of “1” if they responded 
“not well” when asked about how the sprays work for them, and also if the sprays were 
defined as bothersome or unwanted side-effects were mentioned. The Recall Screen measured 
potential problems in remembering all doses. The question about multiple doses in the 
original BMQ was changed, since the patients in our study were instructed to use the sprays 
twice a day. Instead, two potential problems were included. The patients received a score of 
“1” if they answered “yes” to any of the questions. The Access Screen analyzed barriers. The 
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question about problems paying for the medication was excluded from our BMQ. Patients 
received a score of “1” if they answered “yes” to any of the three questions (see questions in 
Appendix C.). 
During the evaluation of the BMQ the subtotals for each screen were calculated by 
adding up the scores for each question. If the score of a screen was ≥1, the subtotal for the 
screen was “1”, and in that case the screen indicated potential non-adherence or the presence 
of the defined barrier. The ARS is a summary scale constructed by adding up the subtotals for 
each screen. It measures potential non-adherence and the number of factors influencing 
patient behaviour. 
 
3. Results 
 
The 12-month adherence to the Amphotericin B nasal spray 
 The records related to the amount of medication self-administered did not reveal any 
significant change in patient adherence between the first (97,5 ± 8,1 %) and the last (94,7 ± 
11,5 %) month of the treatment (one-tailed paired sample t-test, p = 0,126). These findings 
correlate with the observation that patients appear to discontinue their medication or deviate 
from the recommended dosing at higher rates in practice settings than in randomized clinical 
trials (42). Even though a moderate decline was seen from month to month, at the end of the 
study the overall adherence was notably above the most commonly documented cut-off point 
for adherence of 80 %. The difference in compliance between the AmB (97,3 ± 8,1 %) and 
placebo (97,2 ± 7,4 %) groups (two-tailed independent sample t-test, p = 0,323), or between 
the male (97,8 ± 7,4 %) and female (96,6 ± 8,1 %) patients (two-tailed independent sample t-
test, p = 0,886) during the 12 months was not significant  
 Figure 7. shows the compliance of patients with drug therapy during the 12th month 
of the study determined from the recorded amount of medication self-administered. 
Approximately half of the patients used the prescribed amount of spray, 37 % missed not 
more than 20 % of the doses, and only 7,4 % were considered to be non-adherent. 
Interestingly the 2 patients who had the lowest compliance rates through the whole study 
period were closely related and lived in the same household. 
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Figure 7. Patient adherence according to the recorded amount of medication self-
administered during the 12th month of amphotericin B nasal spray treatment. 
 
 
Patient adherence determined by self-reporting in the BMQ 
 Through evaluation of the scores obtained in the BMQ, the ARS can be constructed. 
This tool not only indicates non-adherent behaviour, but also provides information regarding 
the factors influencing adherence. The BMQ defines very strict conditions. By admitting a 
missed dose a patient is classified as potentially non-adherent. This might result in the 
previously determined lower sensitivity (80 %) and high specificity (100 %) of the instrument 
(41). Accordingly it is likely that the BMQ underestimates adherence and overestimates non-
adherence. 
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Figure 8. Adherence Risk Scale results demonstrating barriers to adherence 
 
 Among those patients whose recorded data did not indicate non-adherence, in two-
thirds of the cases the BMQ demonstrated at least one barrier to adherence. The most 
common barrier to adherence was motivational, since 48,1 % of the patients mentioned 
negative beliefs concerning the efficacy of the treatment or bothersome side effects. An 
access barrier was identified for every third patient, most mentioning a malfunction of the 
spray pump or running out of medication too early. Only 25,9 % of the patients admitted or 
implied the existence of recall barriers (Figures 8 and 9.). 
Figure 9. Adherence Risk Scale results demonstrating self-reported non-adherence 
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 The addition of four questions to the BMQ regarding the regularity of use throughout 
the whole study period yielded more detailed information. The following results were 
obtained. Intra-year regularity: 85,2 % answered “constant regularity”, 11,0 % of the patients 
used the sprays “more regularly during the early months” and only 3,7 % admitted “irregular 
use”. The regularity of missed doses: 44,4 % “never missed a dose”, 44,4 % “missed a dose 
around once a month”, 3,7 % missed doses occasionally (1-2 doses a week), and only 2 
patients (7,4 %) missed doses every day. When use of the sprays was compared between the 
two groups, the adherence in the placebo group always proved to be higher. Fewer doses were 
omitted and the regularity of use was also higher. This observation may be linked to the 
frequency of adverse events experienced. 
 
Adverse events 
 AmB applied topically may produce local irritation, pruritus, and skin rash (43). The 
previously discussed seven clinical studies documented various side-effects in connection 
with local AmB treatment such as nasal mucosal inconvenience and a burning sensation, 
nausea or headache. The incidence of adverse events amongst patients treated with AmB 
nasal sprays or lavages in those studies lay in the range from 13,3-66,0 %. 
 During our study the following side-effects were reported in the AmB group: local 
irritation (7,7 %) and headache (7,7 %); while in the placebo group: loss of smell (7,1 %) and 
local irritation (7,1 %) was mentioned. It should be noted that loss of smell and local irritation 
can also considered being symptoms of CRS. The regularity of the observed adverse events is 
summarized in Table 5. 
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Table 5. Adverse events in the two groups of patients receiving amphotericin B nasal spray or 
placebo. (Data from 27 patients who completed the BMQ.) 
Incidence of adverse events Amphotericin B Placebo 
N % N % 
Once 0 0 1 7,1 
Sometimes (once a month) 4 30,7 2 14,2 
Regularly (once a week) 0 0 1 7,1 
Always 3 23 0 0 
Total 7 53,8 4 28,6 
Never 6 46,2 10 71,4 
 
 According to our findings the incidence and also the regularity of side-effects were 
higher in the AmB group than in the placebo group. The overall incidence in the AmB group 
was 53,9 %, as compared with only 28,6 % in the placebo group. 
 
Comparison of the adherence measurement methods 
The combination of the two methods is considered superior to reliance on either of the 
single methods, since both have advantages and disadvantages. Recording of the amount of 
medication self-administered gives a more precise and objective continuous variable, but no 
details about the circumstances of drug use or factors influencing the attitude of the patients 
can be measured. Such recording of drug use have been found to overestimate the actual 
adherence behaviour (40). This holds for our study too, since 92,6 % of the patients were 
defined as adherent (adherence > 80 %) on the basis of the medication records. The scoring of 
the BMQ is too strict and its sensitivity is lower than its specificity; thus it underestimates the 
actual adherence. Consequently, we considered it to be less reliable for the numerical 
determination of patient adherence. We had to find that only 29,6% of our patients were 
categorized as totally adherent (adherence = 100 %) by the Regimen Screen. Hence, no 
statistical correlation exists between the outcomes of the two methods (Fisher's exact test: χ2 = 
4,29; df = 1; p = 0,87). The actual adherence is most likely somewhere between the two 
adherence results. Another problem we had to face was that the spray-holders contained only 
the amount of solution necessary for a 30-day period. If the patient used the spray incorrectly, 
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for example administering too many doses at a given time, the omission of doses on different 
occasions could not be measured with this method. Additionally, improper handling or 
storage of the spray-containers may have resulted in leakage and the loss of spray solution, 
thereby resulting in falsely high adherence measurement results. 
 It can be stated that patient adherence was relatively good; only a moderate decline 
was seen during the 12 months. At the end of the study, the overall adherence was 94,7 ± 11,5 
%. During the last month of treatment, 55,6 % of the patients were totally adherent, in 37 % 
sporadic non-adherence was measured, and only 2 patients (7,4 %) were categorized as non-
adherent. Such a high adherence rate might be explained by the fact that most of the present 
patients suffered from symptoms which greatly deteriorate the quality of life, and had had 
several previous operations; accordingly, they were very determined and had a good 
awareness of their medical state. Moreover, during the study a good relationship was created 
between the patients, the physician and the pharmacist. The ARS constructed from the scores 
of the BMQ indicated the presence of self-reported non-adherence and factors influencing 
adherence. From the ARS, we concluded that motivational barriers influenced the adherence 
in 48,1 % of the patients. Some patients had doubts about the efficacy of the treatment, and 
most of the patients (especially in the AmB group) experienced side-effects or bothersome 
features. Access barriers occurred in 33,3 %, probably because of an inappropriate use or 
dosage of the medication or occasional malfunctioning of the spray apparatus. Recall was the 
least frequent (25,9 %) barrier to adherence. 
Although the drug intake records did not indicate a significant difference in adherence 
between the two genders or the two medication groups, the answers to the BMQ revealed that 
patients deviated from the prescribed dosing regimen more often in the AmB group. This 
observation might be linked to the higher incidence of side-effects caused by AmB. 
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E. Conclusions and overview about amphotericin B antifungal treatment in 
Chronic Rhinosinusitis with Nasal Polyposis 
 
Fungal organisms can give rise to extremely serious acute and chronic sinonasal 
infections in immune-compromised hosts (8, 11, 12). The fungal etiology of CRS in immune-
competent patients is still a topic of considerable debate and needs further clarification (8, 12, 
17, 20, 44, 45). AFRS is a well-known, but relatively rare form of CRS, which is 
characterized by IgE-type immune reactions against fungi cultured from the sinuses. Collins 
et al. (46) reported the presence of local specific IgE to fungi in the EM of some CRS 
patients, but even in those cases no systemic IgE to fungi was detected. They also noted the 
presence of local specific IgE to fungi in all the CRS patients, with positive fungal cultures. 
The consensus of the Workshop on Fungal Sinusitis on terminology and disease classification 
of fungal rhinosinusitis has been published recently (9). 
However, there are at least three reasons why some investigators doubt the relevance 
of fungi in CRS. First, the incidence of fungal colonization in patients with CRS is similar to 
that in healthy individuals (3, 17, 20). Secondly, the presence of EM is not always associated 
with a positive fungal culture, and moreover the group of CRS patients with EM includes 
subgroups based on the presence of fungi in the EM and on IgE-mediated fungal 
hypersensitivity that share clinical characteristics (16). The third important fact is that bacteria 
have also been isolated in the sinus cavities of patients with positive fungal cultures; it 
therefore remains unclear whether intranasal fungal antigens exacerbate the chronic 
inflammatory response or are simply present coincidentally in patients with CRS (3). 
There are important clinical observations too which cannot be ignored and which point 
to the possible etiological role of fungi in CRS. These are as follows: 
1. Gosepath et al. (47) recently successfully proved the presence of DNA fragments of 
Alternaria species in the sinonasal mucous membranes of patients with CRS, concluding that 
the fungal antigen is transported from the EM to the small vessels of the nasal mucous 
membranes by the antigen presenting cells (macrophages), triggering eosinophil infiltration.  
2. Shin (45) demonstrated that the levels of serum IgG to Alternaria sp. and 
Cladosporium sp. were higher in patients with CRS than in healthy individuals. 
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3. The presence of specific IgG antibodies correlated with increased IL-5 and IL-13 
levels during exposure to Alternaria sp. in vitro, but this did not hold controls (45). 
4. Ponikau et al. (18) reported that treatment for 6 months, with regular application of 
a nasal lavage containing AmB resulted in decreased concentrations of both neurotoxin and 
IL-5 originating from eosinophilic cells. In contrast, the concentrations of both mediators 
increased in the placebo group, though the changes were not significant. The observations of 
other researchers on the inflammatory mediators did not confirm these results (48, 49). If the 
fungal etiology is true, it would be reasonable to recommend antifungal treatment to patients 
with CRS in order to decrease or eliminate the fungal load and achieve a symptomatic 
improvement. 
The question arises as to what other causes could have led to the ineffectiveness of 
AmB treatment in almost half of the previously published (methodologically not always 
correct) clinical studies (Table 1.). There are a number of possibilities: 
1. CRS is a multifactorial disease: immune deficiency, genetic factors, anatomic 
variations, atopy and environmental factors such as air pollution and smoke are predisposing 
factors (3). 
2. The compliance may not have been satisfactory during the course of long-lasting 
examination protocols and it was usually not taken into consideration in earlier clinical 
studies (31). 
3. Differences in sensitivity of the various fungi to AmB (50). 
4. Differences in effectiveness of the mechanisms repairing the direct membrane 
damage and the consequences of oxidative stress (51). 
5. In patients with advanced CRSwNP the amount of drug that penetrates to the 
bottom of sinuses filled with EM and polyps may be insufficient. 
The experience gained so far indicates that the results of oral antifungal treatment are 
rather confusing (52, 53). Our clinical study does not justify the need for the administration of 
AmB nasal spray for 12 months following endoscopic nasal polypectomy. The 
methodological errors involved in the studies conducted so far lead us to think that it is an 
oversimplified explanation that fungi are “innocent bystanders”. Our results and the data 
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available draw attention to the necessity of integrated further clinical studies, with improved 
methodology. Treatment modalities should be applied on a case-by-case basis. Future 
research should focus on the selection of the CRS patients who will certainly benefit from 
antifungal therapy (15, 16). Particular attention should be paid to the diagnosis and treatment 
of patients with aspirin intolerance among those who require revision surgery, and to the 
recognition of those patients who will benefit from specific immunotherapy or prolonged low-
dose macrolide therapy (3). 
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V. Section Two: Analytical part 
A. Introduction of polyene antibiotics and the possibilities for analytical 
methods 
 
AmB is a polyene antifungal agent produced by Streptomyces nodosus. Like other 
polyenes (for example nystatin, natamycin or meparticin) AmB has a cyclic structure closed 
by an internal ester bond and consists of two parts: (a) a rigid apolar part of conjugated double 
bonds (seven in the case of AmB) which is responsible for the marked lipophilicity of the 
molecule; and (b) a polar part comprising a large number of hydroxyl groups. It also 
possesses an amino sugar (mycosamin) and a carboxyl group that is present as zwitterions. 
These properties of AmB are responsible for the comparative insolubility of the compound in 
organic solvents (Figure 10.). Although it is a particularly insoluble substance in inorganic 
solvents as well, it can be dissolved in DMSO and dimethylformamid. The presence of bile 
salts (sodium deoxycholate) allows the formation of mixed micelles with AmB and 
solubilisation of the antibiotic. Its antifungal spectrum is very broad and is not restricted to 
fungi since polyenes are active against certain protozoa and algae, but do not possess any 
antibacterial or antiviral activity. AmB is the major first-line antifungal agent and is 
considered to be the most effective in a number of clinical systemic mycoses, however its use 
can be limited by its toxicity when used parenterally, whereas orally its tolerability is 
excellent since it is very poorly absorbed (<5%). The very great majority of fungi are 
susceptible to very low concentrations of AmB, generally at a MIC of <0,5 μg/ml. In vitro 
AmB exerts fungicidal activity after 3 hours, but this activity does not persist for more than 
48 hours (26, 54). 
AmB’s antifungal effect (fungicidal or fungistatic, depending on the applied 
concentration) is based on the interaction of AmB with plasma membrane sterols and other 
AmB molecules, in which it forms pores. As hollow cylinders are formed within the lipid 
bilayer the ions and the essential cell constituents can escape, resulting in the death of the cell. 
The AmB-sterol complex induces disorganization of plasma membrane by this way 
decriptification of cell constituents. The selectivity of AmB for the fungal cell originates from 
the greater affinity for ergosterol – the major component of fugal membrane-, than for 
cholesterol present in mammalian membranes (26). 
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Figure 10. Chemical structure of amphotericin B (formula from Ph. Eur. 6.) 
 
Analysis and quantitative determination of polyenes can be carried out with different 
methods such as chemical and microbiological analysis. The chemical measurements are 
based on the detection of the light absorption of the unsaturated chromophore segment of the 
molecule. Samples containing AmB can be measured directly with spectrophotometry or after 
chromatographic separation. During the past two decades several HPLC methods have been 
published and used (55, 56). With the aid of microbiologic detection methods directly the 
antimicrobial effect can be measured. Such methodologies are agar diffusion and 
turbidimetric bioassays (54, 57). Bioassay measurements or methods were rarely published 
even though microbiological assays are the official methods for the quantitative analysis for 
AmB (and also nystatin) prescribed by the American (USP. 21.) and European (Ph. Eur. 6.) 
pharmacopoeias. Bioassays are favoured because of the chemical instability of the molecule 
and the homogeneity and purity of the preparations might differ due to the fermentation and 
extraction procedures. 
 The two types of analytical methods differ fundamentally from each other. With the 
aid of chemical methods, those parameters (polarity, light absorption) are studied which are 
directly associated to the molecular structure of the molecule. The technical, financial and 
instrumental requirements of such measurements are higher - for instance HPLC apparatus is 
required -, but they are relatively fast and reproducible quantitative measurements can be 
performed. From the aspect of the measurement of biologically active substances, a major 
disadvantage is that no information can be gathered regarding the antimicrobial effect of the 
examined samples. On the other hand with the aid of biological assays directly the biological 
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effect can be measured. It should be emphasized, that such methods are typically more time 
consuming and the reproducibility is not as good with chemical analysis. 
 
B. The question of stability and optimal storage conditions for clinical study 
medications 
 
As emphasized earlier in the clinical part of the thesis, the stability testing of study 
medications is an important factor because, on one hand patients needed to use the sprays for 
a year long period and on the other hand the long term stability of AmB is questionable in 
water based solutions. 
Previously published papers were screened and reviewed to evaluate the question of 
stability. Our results are summarized in Table 6.. Also the outcomes of these studies are 
illustrated in Figures 11. and 12. from the aspect of storage temperature. 
It can be seen in the table, that earlier microbiological assays were used for the 
analysis, but during the last two decades chromatographic determinations were applied. From 
this aspect the comparison of the results could be rather difficult, but since these studies are 
short term (less than 24 hours), this problem is of no significance. The tested solutions are of 
different AmB concentrations ranging from 0,05-100 mg/ml and were all made of 
commercially available pharmaceutical preparations. Five percent dextrose, as the only 
recommended solvent of dilution for Fungizone, was used most commonly. For the sake of 
easier comparability and transparency only the results of light protected samples are 
presented. It has to be stated, that not all authors have tested the effect of light exposure. 
When comparing the results of studies using different containers for the solutions, the 
conclusion can be drawn, that probably no strong correlation exists between the material of 
the container and the stability. 
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Table 6. Summary of published stability tests of amphotericin B solutions. 
Author 
Shadomy S. 
(58) 
Block E.R. 
(59) 
Kintzel P.E. 
(60) 
Mitrano F.P. 
(61) 
Juarez J.C. 
(62) 
Dentinger P. 
(63) 
Manosori A. 
(64) 
Groeschke J. 
(65) 
Year 1973 1973 1991 1991 1997 2001 2003 2006 
Method Bioassay Bioassay HPLC HPLC HPLC HPLC HPLC HPLC 
Concentration 0,05 mg/ml 14 mg/ml 1,4 mg/ml 0,25 mg/ml 1 mg/ml 100 mg/ml 5 mg/ml 7,4 mg/ml 
Prepared 
from 
Fungizone - Fungizone Fungizone Fungizona Fungizone Fungizone Fungizone 
Excipients 
5 % dextrose, 
0,2 % NaCl 
- 5 % dextrose 5 % dextrose - 
citric acid, 
sodium 
phosphate 
- 
1,4 % sodium 
hydrogen 
carbonate 
Container Glass Glass PAB PVC Glass Polyethylene Glass Glass 
Protected 
from light 
yes yes yes yes yes yes yes yes 
Stability (4-6 
°C) 
≥8 hours - ≥1,5 days ≥35days ≥30 days - 11,4 days ≥15 days 
Stability (20-
25°C) 
≥8 hours ≥1 day ≥1,5 days - ≥30 days ≥93 days 4,1 days 4 days 
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Figure 11. Stability of amphotericin B solutions stored below room temperature (4-8 °C) 
 
On Figure 11. and 12. data from Table 6. are plotted. It can be seen that at lower 
temperature (4-8°C) the solutions are more stable. The refrigerated samples are considered to 
be relatively stable and the outcomes of the studies are in correlation with each other. This 
statement not holds for samples stored at room temperature. The longest stability test 
designed by Dentinger et al. shows no loss of concentration at 20 °C for more than 30 days, 
while Manosori and Groeschke concludes, that samples are stable for not more than 4 days at 
room temperature. 
Figure 12. Stability of amphotericin B solutions stored at room temperature (20-25 °C) 
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 The correct interpretation of these controversial results is rather difficult and could be 
misleading, so when the question of stability arose during the preparation of the pilot clinical 
study, the organization of a new stability test seemed to be the most reliable source of 
information. As mentioned before, bioassay if the official quantitative analytical method for 
polyenes, thus the combination of both chemical and microbiological methods was proposed 
since this way more detailed information could be gathered regarding the physic-chemical 
changes in the samples. 
 
C. Results of the stability test performed with spectrophotometry and agar 
diffusion. Contrast between the outcomes of the analytical methods. 
 
In our study we investigated the stability of 5mg/ml AmB solutions (Fungizone®) 
with chemical (spectrophotometry) and biological (bioassay) detection. The effect of storage 
temperature and the addition of 5% glucose were evaluated on the stability of the solutions for 
three months. 
Study samples were prepared from Fungizone® (Bristol-Myers Sqiubb) which was 
diluted in 10,0 ml water for injection to give 5 mg/ml solutions. For the 5 % glucose 
containing samples glucose solutions (from glucosum anhydricum, Ph.Eur.5, 
Hungaropharma) were sterilized with 0,22 μm membrane filter. During spectrophotometric 
quantification 0,1 N NaOH was used for dilution and Candida albicans ATCC 90028 test 
strain was applied for bioassay. The composition of the test agar medium was: LAB-LEMCO 
(Oxoid) 5,0g; peptic peptone (Reanal) 10,0g; NaCl (Ph.Eur.5., Hungaropharma) 5,0g; 
Na2HPO4 (Reanal) 4,0g; Agar-agar (Merck) 20,0g; and 1000 ml deionised water. 
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Figure 13. Results of the spectrophotometric measurements show only minor changes in 
concentration. 
 
The 3,33 ml stability samples (n=3) were stored in refrigerator (4 °C) and at room 
temperature (20-23˚C) in light protective glass containers. During the 112 day period, on 0., 
7., 14., 21., 28., 35., 49., 63., 84. and 112. days, a 20 μl sample was removed from the 
container and used for the two analytical procedures. Chemical determinations were 
performed with Specord M40 spectrophotometer at the absorption maxima of AmB (265, 384 
and 407 nm). Results are displayed as the averages of the three measurements for each 
sample. Microbiologic measurements were done in 18 cm diameter glass petri dishes filled 
with 120 ml assay medium inoculated with the test organism. Holes with the diameter of eight 
millimetres we cut in the agar medium and 200 μl of calibration or study samples were 
applied in them. Freshly prepared Fungizone was used for the production of calibration 
solutions and sterile deionised water was used for the dilution of these samples. The petri 
dishes were incubated at 30 °C for 24 hours and the inhibition zones were measured with a 
0,1 mm precision scale. The dose response curve was determined and with the above 
mentioned conditions it proved to be linear in the concentration range of 0,625-5,0 µg/ml 
(r
2≈0.96). From the diameter of the inhibition zones, the concentrations of the samples were 
calculated. 
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Figure 14. Bioassay measurements indicate major changes in antifungal activity. 
 
The two detection methods showed strikingly different results. According to the 
chemical analysis the samples are considered relatively stable under all observed conditions 
(loss of concentration is: 14,2% at 20°C and 4,5% at 4°C) as can be seen on Figure 13. As 
opposed to chemical analysis, bioassay (Figure 14.) shows complete loss of antifungal 
activity after 35 days of storage, at room temperature and notable decrease can be observed at 
4°C (glucose containing solution 17,6%; glucose free solution 37,2%). Storage temperature 
had significant effect (p<0,05), while 5% glucose had no significant effect (p>0,05) on the 
stability of the examined solutions. The results of our measurements with quantitative data 
(mean ± SD) are summarized in Table 7. We estimated the shelf life of the glucose-free 
solutions, being stored at 4°C, to be 30 days in accordance with our bioassay results. 
Interestingly in the case of bioassay, during the first half of the test period the antifungal 
activity did not decrease, but instead seemed to increase under all examined circumstances. 
For the samples stored at room temperature this positive change in activity is even more 
intense, also the presence of glucose seemed to have an additive effect in this phenomena. 
 This information drew our attention to the major differences that can be detected with 
the two different methods. There are presumptions, but no facts that could explain our 
observations. Most probable is that colloidal change occurs in the solution resulting in the 
decrease in capability of AmB to diffuse within the agar layer, this way producing smaller 
inhibition zones. Unfortunately this theory does not answer the initial increase in antifungal 
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activity. It has been reported by Romanini et al. (66) that AmB in aqueous medium forms 
higher molecular weight aggregates which decreases it’s activity. The size of these is 
estimated at 200 molecules. It has also been published, that AmB/sterol channels are 
produced in the fungal membrane, consisting of eight AmB and eight sterol molecules (67). It 
could be possible, that during the initial self association phase, when smaller aggregates of 
just couple of molecules exist, these channels might form faster or more efficiently, resulting 
transitionally in a more potent microbiological activity. 
Table 7. Stability test results for 5mg/ml amphotericin B solutions (Fungizone®) with 
chemical (spectrophotometry) and biological (bioassay) detection. (mean±SD, n=3) 
Spectrophotometric measurements Bioassay measurements 
Time Temp. 
glucose-free samples 
glucose containing 
samples Time Temp. 
glucose-free 
samples 
glucose containing 
samples 
mean SD mean SD mean SD mean SD 
0. day 20 ºC 100,0 ± 0,37% 100,0 ±0,37% 0. nap 20 ºC 100,0 ±5,06% 100,0 ± 9,83% 
7. day 20 ºC 91,4 ± 0,27% 97,5 ±4,43% 7. day 20 ºC 99,0 ±23,88% 106,1 ±25,92% 
14. day 20 ºC 90,2 ± 1,11% 94,6 ±0,57% 14. day 20 ºC 125,4 ±13,72% 155,2 ±27,71% 
21. day 20 ºC 93,9 ± 1,33% 93,9 ±1,31% 21. day 20 ºC 136,5 ±18,05% 148,2 ±13,92% 
28. day 20 ºC 91,3 ± 1,29% 89,2 ±1,21% 28. day 20 ºC 36,8 ±6,22% 85,6 ±8,36% 
35. day 20 ºC 90,4 ± 1,23% 93,0 ±1,94% 35. day 20 ºC 0,0  0,0  
49. day 20 ºC 87,5 ± 1,30% 84,6 ±1,12% 49. day 20 ºC 0,0  0,0  
63. day 20 ºC 86,1 ± 1,50% 88,7 ±1,40% 63. day 20 ºC 0,0  0,0  
84. day 20 ºC 86,7 ± 0,65% 85,7 ±0,76% 84. day 20 ºC 0,0  0,0  
112.day 20 ºC 85,9 ± 1,01% 85,8 ±0,39% 112.day 20 ºC 0,0  0,0  
0. day 4 ºC 100,0 ± 1,07% 100,0 ±1,07% 0. day 4 ºC 101,5 ±5,06% 100,0 ±9,83% 
7. day 4 ºC 101,1 ± 1,85% 101,6 ±0,97% 7. day 4 ºC 93,6 ±45,43% 95,8 ±21,62% 
14. day 4 ºC 97,8 ±1,11% 98,3 ±0,53% 14. day 4 ºC 83,6 ±1,62% 107,2 ±25,04% 
21. day 4 ºC 96,9 ± 017% 99,1 ±1,07% 21. day 4 ºC 123,5 ±20,55% 153,5 ±7,20% 
28. day 4 ºC 98,0 ± 1,44% 95,4 ±0,96% 28. day 4 ºC 120,5 ±28,76% 104,1 ±22,27% 
35. day 4 ºC 98,7 ± 4,32% 99,1 ±0,50% 35. day 4 ºC 113,7 ±23,07% 156,2 ±7,25% 
49. day 4 ºC 95,6 ± 0,64% 93,7 ±0,20% 49. day 4 ºC 69,8 ±16,62% 105,2 ±16,07% 
63. day 4 ºC 95,1 ± 1,74% 99,9 ±0,57% 63. day 4 ºC 74,0 ±14,41% 122,2 ±4,54% 
84. day 4 ºC 95,1 ± 0,34% 97,9 ±1,08% 84. day 4 ºC 51,8 ±9,01% 74,7 ±20,33% 
112.day 4 ºC 95,2 ± 0,24% 95,8 ±0,95% 112.day 4 ºC 62,8 ±12,21% 82,4 ±27,91% 
 
 Nevertheless it can be stated, that such changes occur in the solutions that do 
significantly affect the microbiologic effectiveness of AmB while the chemical structure 
(principally the polyene segment and its light absorption properties) is not altered 
significantly. Thus the proper investigation of stability is of great importance when 
determining the shelf life of medications. After the stability test had been completed, our 
intention was to do the optimization of chemical and biological analytical methods in the 
interest of getting better understanding of the changes occurring in the solutions. The 
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chemical analysis can be improved if a more sensitive and detailed test method is used, such 
as high-performance liquid chromatography (HPLC). With the aid of chromatographic 
separation not only the identification and quantification of AmB can be achieved, but also the 
separation of degradation products is possible. In addition, a more precise bioassay method 
was needed to reduce the coefficient of variation when measuring antifungal activity. In this 
way the initial activity increase and the following decrease can more reliably be documented 
and its importance can be evaluated. 
 
D. Chemical methods 
1. Introduction 
 
As described previously, chemical methods are suitable for the identification and 
quantification of the antifungal substance. By the application of chromatographic methods, 
not only the amount of polyene molecules (containing the conjugated double-bond segments) 
can be determined, but also separation allows us to distinguish molecules with different 
physicochemical properties. 
Main, minor components and degradation products were screened for in Fungizone 
(Bristol-Myers Squibb). Chromatographic parameters, solvent composition and pH were 
altered to identify best parameters for optimal separation with HPLC. We intended to 
optimize earlier methods to achieve the best available separation of heptaene and tetraene 
components and to work out a method for quantification of the main component. 
With TLC, the separation and visualization of the minor heptaene and tetraene 
components is more difficult to achieve due to the small concentration of the substances 
(approximately 1 per cent of the main heptaene AmB). Even so we intended to separate the 
main component from the others so that by the application of microbiologic detection (the 
method of direct bioautography is described in Chapter VI.E.3. of my thesis) antifungal 
activity could be visualized of the minor components or the degradation products. In this 
manner our main goal was to achieve reliable and reproducible separation for AmB with 
eluents suitable for biologic detection 
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2. HPLC measurements 
a) Materials and methods 
 
Our method was adapted and further improved based on previously published and 
evaluated literature data presented in Table 6. The HPLC system consisted of: Waters 600 
pump, Rheodyne 7125 injector, Waters 996 PDA detector and Millenium software. 
Measurements were performed at ambient temperature. A volume of 25 µl samples were 
injected onto 250 x 4,6 mm C18 (Chromsil C18, 6 µm) columns, with a flow rate of 0,25 
ml/minute. Heptaene components were measured at 407 nm, while tetraenes were determined 
at 305 nm. HPLC grade solvents were used for the eluents: acetonitrile (MeCN, Chromasolv, 
Sigma-Aldrich), methanol (MeOH), sodium acetate - EDTA buffers (4,1 g NaAc + 1,1 g 
Na2EDTA +1000 ml deionised water) set to different pH values with acetic acid. Nystatin 
(Hungaropharma, Ph.Eur.5.), piroxicam (Hotemin inj., EGIS) and 4-nitro-1-naphthylamin 
(Aldrich) were tested as potential internal standards.  
 
b) Results and conclusions 
 
Although earlier publications did not lay emphasis on, or did not document presence 
minor components in AmB samples, even after preliminary measurements we could visualize 
several minor components in the chromatograms. To improve separation, the optimization of 
solvent system was performed and the following observations were made: increasing the ratio 
of buffer (Figure 15.a.) or augmenting the percentage of methanol within the organic phase 
(Figure 15.b.) improves the separation of different minor components, but at the same time 
notably increased retention times. 
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Figure 15.a. Effect of the ratio of buffer in the eluent system on separation 
 
Figure 15.b. Effect of the ratio of methanol within the organic phase on separation 
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Figure 15.c. Effect of buffer pH on separation 
 
When lowering the pH of the buffer (Figure 15.c.), the separation of minor 
components from the main heptaene AmB is better. Unfortunately most tetraenes (amongst 
which amphotericin A can be found) are in such small proportion, that documentation and 
identification is rather difficult and cannot be well separated from heptaenes found in higher 
concentrations. With our optimized eluent system and the aid of the gradient program 
described in Table 8., four heptaene components can be detected besides AmB main 
component at 407 nm. The amount of these constituent is about one hundredth of the main 
AmB. Only traces of tetraenes can be detected in Fungizone at the wavelength of 305 nm 
(Figure 16.). Probably amphotericin A - the most important minor component of AmB, which 
does not have antifungal effect - is amongst these peaks. 
From the previously used internal standards we have tested nystatin, piroxicam and 4-
nitro-1-naphthylamint and had to find that the later proved to be the best, because nystatin’s 
spectrum and retention overlapped with the tetraenes and piroxicam’s absorption maxima was 
too distant from the maxima of AmB. 
 With the aid of the above described chromatographic method several minor 
components can be detected in AmB samples. To our best knowledge, the separation of these 
components has not been published before. 
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Table 8. Eluent composition (v/v) and gradient program for the HPLC analysis of 
amphotericin B and minor components 
Eluent composition A (%) B (%) 
Acetonitrile 32,4 50,4 
Methanol 12,6 19,6 
Buffer Na-Ac EDTA (pH 5) 55,0 30,0 
Gradient program   
Time (min.) 
Flow 
(ml/min.) 
A (%) B (%) 
0,05 0,25 100 0 
4,0 0,25 20 80 
12,0 0,25 20 80 
14,0 0,25 100 0 
30,0 0,25 100 0 
 
Figure 16. Heptaene and tetraene components in Fungizone by HPLC 
 
The precise detection and identification of them is of great importance during a stability test 
where degradation products are formed and the amount of main (and active) antifungal is 
constantly changing. The new chromatographic parameters can beneficially be used during a 
stability test in the future. 
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3. Thin Layer Chromatography 
a) Materials and methods 
 
Solutions of AmB (0.5 mg/ml) were prepared in a solvent mixture composed of 30 % 
DMSO (analytical grade, Merck KGaA, Darmstadt, Germany), 60 % methanol (HPLC grade, 
Sigma-Aldrich Chemie GmbH, Steinheim, Germany) and 10 % distilled water from three 
different substances: (1) Vetranal - amphotericin B trihydrate Riedel-de-Haën (Sigma-Aldrich 
Chemie GmbH, Steinheim, Germany); (2) freshly prepared Fungizone (5 mg/ml; Bristol-
Myers Squibb, Epernon, France) and (3) degraded Fungizone solution stored at room 
temperature for two years. The solutions were spotted on 20x20 cm pre-coated silica gel 60 
aluminium sheets (Merck, Darmstadt, Germany Art.No. 5553) – cut into 10x10 cm sections – 
by use of disposable 1 μl micro pipettes. TLC adsorbents were washed with methanol, dried 
and preconditioned by heating at 120 °C for 3 hours. Ascending development to a distance of 
8 cm was performed in a previously saturated (for 20 minutes) CAMAG (Muttenz, 
Switzerland) chromatographic chamber. After development the plates were dried and UV 
active spots were detected at 366 nm. Photographic documentation was performed with a 
digital camera (Nikon Coolpix 5700, resolution 2560x1920 pixels, Nikon Corporation, 
Tokyo, Japan). Densitometric evaluation was performed with CAMAG TLC Scanner II V3.15 
with CATS Version - 3.14. (CAMAG, Muttenz, Switzerland). Scanning conditions were: slit 
dimension, 12 x 1.2 mm; monochromator brandwith, 30 nm; light source, deuterium lamp at 
λ=385 nm. Chromatographic developments were performed at room temperature. The TLC 
sheets were dried also at the same temperature, protected from light with good ventilation to 
reduce the risk of the degradation of the substance. 
 
b) Results and conclusions 
 
The most detailed review regarding the TLC separation of polyenes can be found in 
the publication by Thomas (54). Out of the 7 potential eluent systems we chose to test the 
ones with RF values over 0.2 in hope of better separation and biologic detection (Table 9.). 
Because solvents or their residues can modify the microbiologic detection, eluent selection is 
considered to be a complex problem for direct bioautography. 
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Table 9. Formerly documented mobile phases tested on silica gel layers and the 
optimized eluent composition for TLC and direct bioautography 
Mobile-phase components 
Volume 
ratio 
(v/v) 
Measured 
RF 
Running 
time (min) 
No. of 
components 
at 366 nm 
A Methanol – Acetone – Acetic acid 8:1:1 0.63 25 1 
B 1-Butanol – Pyridine – Water 3:2:1 0.78 90 1 
C 
Chloroform – Methanol – 
Borate buffer (pH 8.3) 
7:5:1 
main:0.29 
minor:0.21 
35 2 
D 
1-Butanol – Ethanol – Acetone – 
conc. Ammonia 
2:5:1:3 0.25 60 1 
E 
Optimized eluent: Chloroform – 
Methanol – 
Borate buffer (pH 8.3) 
4:5:1 
main:0.46 
minor:0.31 
27 2 
 
As presented in Table 9., with the application of eluent C two spots can be observed on the 
plates at 366 nm. For the better separation of the components and future identification of 
degradation products we optimized this eluent. Alteration of pH and ionic strength of the 
buffer did not affect separation, but increasing the amount of the inorganic component 
resulted in higher RF values and an augmented distance between the spots. Raising the amount 
of methanol within the organic phase increased RF values at the expense of the separation of 
the components. Our final eluent E has the advantages of a relatively fast TLC development 
and the use of easily evaporating organic solvents, appropriate for microbiologic detection. As 
shown on the densitogram (Figure 17.) the major component of AmB is at RF = 0.46. 
Separation of minor heptaenes is relatively difficult to achieve and detection of the 
components is complicated, because the UV visualization of minor components can only be 
achieved at high concentrations (above 100 ng/spot). Unfortunately at higher concentrations 
the spots are overloaded and tailing is observed, thereupon the separation of the components 
is flawed. 
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Figure 17. Densitogram of amphotericin B (250 ng/spot) with main component (1) and 
minor component (2) at 385 nm 
 
 At concentrations of 250 - 500 ng/spot both the major and one minor component can 
be seen under the UV light. Our intention was to document changes in the composition of 
degraded solutions and also to identify degradation products in Fungizone 5 % solutions. 
When measuring the three different samples (analytical standard, fresh and degraded 
Fungizone) we had to find, that compared to the analytical standard (Vetranal) and the freshly 
prepared Fungizone no discrete degradation product or minor component can be separated 
(Figure 18.). 
Figure 18. Densitogram of freshly prepared and degraded samples at 385 nm. 
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Based on the densitometric analysis (250 and 125 ng) it can be stated, that the main 
component of AmB has degraded because not only the area under the curve, but also the 
height of the peak is reduced in the densitogram of the stored/degraded samples 
(measurement data (n=1) presented in Table 10.). Probably many different products are 
produced which could be causing the “tail” of the peak. From this aspect the TLC method in 
itself is not the most suitable method for the qualitative analysis of degradation products in 
AmB solutions, but it can indeed be a useful marker of degradation. The question arose 
whether the degraded components possess any antifungal effect or not? This question can be 
answered with the aid of microbiologic detection, such as direct bioautography. 
 
Table 10. Analysis of analytical standard, fresh and degraded solutions (5 mg/ml) of 
amphotericin B with densitometry 
Sample of AmB Peak start Peak max Peak end Area 
(250 ng/spot) 
Distance 
(mm) 
Height 
Distance 
(mm) 
Height 
Distance 
(mm) 
Height  
Vetranal 
(standard) 
44.9 6.5 50.9 58.2 56.7 2.0 2571.2 
Fungizone 
(fresh) 
45.9 6.5 50.7 57.5 56.3 0.6 2375.3 
Fungizone 
(stored/degraded) 
42.8 5.0 50.7 32.2 56.3 0.1 1561.9 
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E. Biological methods 
1. Introduction 
 
Biological techniques are useful indicators of antimicrobial potency and degradation, 
resulting in loss of microbiological activity (see illustrative figure in Appendix D.). The 
activity of an antifungal or an antimicrobial substance can be determined by its inhibitory 
effect on microorganisms. Bioassay is used for quantification of such substances which 
cannot be measured adequately by chemical or physical methods and also when the reduction 
of antimicrobial activity could reveal changes which cannot be measured by chemical 
methods. Antibiotic assays are performed by agardiffusion or turbidimetric methods. In case 
of agardiffusion, the sample solutions are measured in cylinders cut in a seeded agar, or disks 
containing antibiotics are placed on the surface of a medium inoculated by a sensitive test 
strain. The concentration / activity of the sample can be calculated from the diameter of the 
inhibition zones. The parallel-line model is an analytical method described by the Ph. Eur. 6. 
for the bioassay of antibiotics (68). The validity of the results requires the log dose-response 
curve to be linear in the measured concentration range. Because the U.S., European and 
Hungarian pharmacopoeias recommend bioassay for the quantification of polyenes, the 
application of agar diffusion method seemed to be an appropriate analytical method. We 
observed that using the conditions proposed in Ph. Eur. 6. (indicator organism and assay 
medium), the reproducibility of the assay was difficult: limit of detection was relatively high; 
inhibition zone borders were indistinct; the agar medium filled with gas bubbles produced by 
the test microorganism (Saccharomyces cerevisiae ATCC 9763) and cracked after 24 hours of 
incubation. These factors lead to the inaccuracy of the assay. For these reasons we tested, 
which assay parameters would be the most optimal for the quantitative measurement of AmB 
during a stability test, where a wide concentration range is aimed to be measured. 
Direct bioautography, as a post chromatographic detection for microbiologically active 
substances, have been used by several authors in different fields of analytical, medical or 
agricultural sciences. Hostettmann (69) describes bioautography methods as very convenient 
and simple ways of testing plant extracts and pure substances. In search of detecting new 
antifungal several methodologies were used and compared, for example Rahalison (70) have 
described the use of series of clinically important antimycotic agents during their experiments 
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and also Wedge and Nagle (71) have tested mixtures of structurally diverse antifungal 
substances (such as AmB). 
 
2. Bioassay with agardiffusion 
a) Materials and methods 
 
 In our study we compared four commonly used assay media: Mueller Hinton Agar 
(MHA); MHA supplemented with 2% glucose and methylene blue (MHA-GMB); Modified 
Antibiotic Medium 12 (MAM-12), the Ph. Eur. 6. antibiotic medium F (F-M) and a medium 
(MHA-E) used in our institute for bioassay (see Appendix E.). As indicator organisms we 
chose Candida albicans (ATCC 90028) and S. cerevisiae (ATCC 9763) both previously used 
for bioassay of AmB. The sterile, melted media prepared in volume of 250 ml were cooled to 
50 °C and maintained at that temperature until dispensed. Prior to dispensing the melted agar 
media were inoculated with 3 ml of the adjusted suspension (absorbance = 0,1 at 600 nm) of 
the indicator organism which was cultivated on Sabouraud's dextrose agar (Oxoid Ltd., 
Cambridge, UK) for 72 hours. Colonies were washed and diluted with sterile physiological 
saline solution. 25 sterile antibiotic assay cylinders (diameter: 8 mm) were placed 
equidistance apart in sterile glass petri dishes (diameter: 250 mm). The cylinders were 
allocated according to a completely randomized design and were loaded with 200 µl sample 
solutions. AmB solutions are prepared from Fungizone (Bristol-Myers Squibb, Epernon, 
France) using the solvent (DMSO, Merck, Darmstadt, Germany) and the buffer (0,2M 
phosphate buffer) indicated in Ph. Eur. 6. for dilution of the samples. Fungizone has been 
used as the raw material for the nasal sprays and also as the subject for the stability test, since 
the pharmaceutical grade substance was inaccessible in Hungary and earlier studies also used 
other formulations of AmB medications. Drug dilutions used for the dose-response curve 
contained 60,0; 24,0; 9,6; 3,84; 1,54; 0,61; 0,25 and 0,10 µg/ml AmB. Three replications per 
dose were performed. A period of diffusion (2 hours at 5 °C) was used to minimize the effects 
of the variation in time between the application of the samples and to improve the regression 
slope. Afterwards the plates were incubated at 30 °C for 48 hours. To determine the dose-
response curve, we photographed the plates in a dark chamber, lit with 20W light, with a 
digital camera (Nikon Coolpix 5700, resolution 2560x1920 pixels) while placing a 10 mm 
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reference scale on the agar surface. Taking three measurements across different diameters, the 
zones of inhibition were determined with a precision of 0,01 mm.  
The applicability of the official bioassay analysis is based on the assumption that the 
log dose-response curve is linear in the measured concentration range. The linear regression 
was tested with curve fit and analysis of variance (ANOVA). A segment of the log dose-
response curve was considered to be linear if R
2≥0,95 and the correlation between the 
logarithm of the dose and the response was significant (p≤0,05). Calculations were performed 
with SPSS 14.0 for Windows (SPSS Inc., Chicago, Illinois, USA). 
 
c) Results and conclusions 
 
Limits of detection and linear segments of the log dose-response curves for the 
examined assay media and test organism are summarized in Table 11. Assay media without 
any glucose (MHA-E and MHA) are unsuitable for bioassay with S. cerevisiae since no 
growth, thus no zones of inhibition can be detected. When media with glucose for S. 
cerevisiae was used, intense gas formation and bubbles were observed after 24-32 hours, 
which reduced the accuracy of determining the inhibition zones. This phenomenon is 
corrigible if after a 30 °C 48 hours incubation, the plates are stored at 5 °C for 24 hours, 
allowing the gases to escape. 
Lowest limit of detection (0,25 μg/ml AmB) can be achieved using MHA-E and C. 
albicans. For the other observed media S. cerevisiae increases the sensitivity of the method, 
however using C. albicans longer linear segments in the log dose-response curve can be 
found, except in the case of MAM-12. The assay parameters suggested by the Ph. Eur. 6. (F-
M and S. cerevisiae) give same results as employing MHA-GMB with S. cerevisiae (Figure 
19.). Exchanging the test organism to C. albicans enables to measure an approximately 6 
times wider concentration range (1,54-60,0 μg/ml), which condition is much suitable for a 
stability test. If a lower concentration is to be detected, the MHA-E with C. albicans is the 
most appropriate choice, since AmB can be detected between 0,25-9,6 μg/ml. 
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Table 11. Limits of detection and linear segments of the log dose-response curves of 
amphotericin B for the observed assay media and test organism 
Medium 
code 
Indicator 
organism 
Limit of 
detection 
(μg/ml) 
Linear segment of the 
dose-response curve 
(μg/ml) 
R² p 
MHA-E 
C. albicans 0,25 0,25 - 9,6 0,967 0,003 
S. cerevisiae       
MAM-12 
C. albicans 3,84 9,6 - 60 1 0,005 
S. cerevisiae 1,54 3,84 - 60 0,998 0,001 
MHA 
C. albicans 0,61 0,61 - 9,6 0,964 0,018 
S. cerevisiae       
MHA-
GMB 
C. albicans 1,54 1,54 - 60 0,966 0,003 
S. cerevisiae 0,61 0,61 - 9,6 0,954 0,023 
F-M 
C. albicans 1,54 3,84 - 60 0,955 0,023 
S. cerevisiae 0,61 0,61 - 9,6 0,974 0,013 
Abbreviations: MHA-E: Assay media used at the University of Pécs; MAM-12: Modified Antibiotic Medium 
12; MHA: Mueller Hinton Agar; MHA-GMB: Mueller Hinton Agar supplemented with 2% glucose and 0,5 
µg/ml methylene blue; F-M: Antibiotic medium F in Ph. Eur. 6. For composition see Appendix E. 
Readability of the inhibition zones is a crucial part of a bioassay analysis. If the borders of the 
zones are more distinct, the reproducibility of the method is better. In our study we 
documented and compared the zones of inhibition for each examined circumstance after 48 
hours of incubation at 30 °C (Figure 20.). Borderlines are more diffuse when S. cerevisiae is 
used as test organism. No growth can be observed on the glucose free MHA-E medium and 
only slight growth is seen on the starch containing MHA medium. In case of employing the F-
M medium and S. cerevisiae as an indicator strain (Ph. Eur. 6. conditions) a double inhibition 
zone is produced, which further reduces the good readability of the zones. Using C. albicans 
as the test organism, both with MHA-E and MHA-GMB media clear and distinct zones of 
inhibitions were documented. 
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Figure 19. Linear segments of the dose-response curves for four selected bioassay 
conditions of amphotericin B. 
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Figure 20. Zones of inhibition of amphotericin B for the studied assay media and test 
organism photographed after 48 hours of incubation at 30 °C. 
 
Abbreviations: MHA-E: Assay media used at the University of Pécs; MAM-12: Modified Antibiotic Medium 
12; MHA: Mueller Hinton Agar; MHA-GMB: Mueller Hinton Agar supplemented with 2% glucose and 0,5 
µg/ml methylene blue; F-M: Antibiotic medium F in Ph. Eur. 6. For composition see Appendix E. 
Our analytical method was validated for the best assay condition found (MHA-GMB 
and C. albicans) according to the ICH guideline (72). Three concentration levels were tested 
(low, middle and high). At each level, samples were prepared in triplicate and results were 
analyzed for the same day to test the repeatability (intra day precision). Accuracy was 
expressed as percentage of the observed and the theoretical concentration. To test the 
precision variation within different days (intermediate precision) measures were repeated on 
three consecutive weeks. Precision data is expressed in percentage relative standard deviation 
(R.S.D). According to our tests the limit of detection (LOD) for the most optimal condition 
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was 1,54 µg/ml and the limit of quantification (LOQ) was 15 µg/ml. In Table 12. the results 
of the method validation are shown. The accuracy of a quantitative bioassay method 
unfortunately can’t be compared with the precision of other instrumental methods such as 
HPLC. Although according to the validation data the accuracy is within the ±5 % range at all 
measured concentrations, the higher deviation at low concentration implies that AmB could 
be more accurately measured at higher concentrations. 
Table 12. Results of method validation 
Theoretical 
concentration 
(µg/ml) 
Measured 
concentration 
(µg/ml) (mean 
n=3) 
Accuracy (%) 
Precision 
Repeatability 
Intermediate 
precision 
R.S.D. (%) R.S.D. (%) 
60,00 58,20 97,00 12,93 9,98 
30,00 30,06 100,21 10,59 5,60 
15,00 15,63 104,19 6,32 24,01 
 
Our aim was to find the most adequate conditions for bioassay quantification of AmB 
during a stability test where a relatively wide range of concentration change can be expected. 
Thus our objectives were to find the parameters where the linear segment of the log dose-
response curve is the longest, the limit of detection is the lowest and the borders of inhibition 
zones are distinct. In our study we evaluated five commonly used assay media and two test 
microorganisms for the quantitative determination of AmB in a water base solution made 
from Fungizone. 
 The assay parameters (F-medium with S. cerevisiae as test organism) recommended 
by the Ph. Eur. 6. were less sensitive and were only applicable for the measurement of a 
narrow concentration range. The borders of the inhibition zones were indistinct and during the 
incubation the medium filled with gases which made the determination of the concentration 
inaccurate. According to our study Mueller Hinton agar supplemented with 2 % glucose and 
0,5 µg/ml methylene blue, inoculated with C. albicans (ATCC 90028) proved to be the most 
suitable bioassay parameters for the measurement of AmB during a stability test, where a 
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relatively wide concentration change is to be measured. The linear segment of the log dose-
response curve was between 1,54-60,0 μg/ml and the inhibition zones could be read easily 
and accurately. 
 
3. Direct bioautography 
a) Materials and methods 
 
 Candida albicans (ATCC 90028) and Saccharomyces cerevisiae (ATCC 9763) fungus 
strains were cultivated on Sabouraud's dextrose agar (Oxoid Ltd., Cambridge, UK) for 72 
hours. One hundred millilitres of Mueller–Hinton broth (Difco Laboratories, Detroit, 
Michigan, USA) supplemented with 2 % glucose was inoculated with the test organism and 
was cultivated for 16 hours at 30 ˘C in an orbital shaker incubator at a frequency of 300 rpm 
(New Brunswick Scientific Innova 40, New Brunswick, NJ., USA). To achieve homogenous 
immersion suspensions, the optical density of the suspensions was set to 0,5 at 600 nm (in 1 
cm light path) with fresh nutrient broth. The plates were immersed in the microbial 
suspension for 15 seconds, placed in a water vapour-chamber for incubation at 37 °C. After 5 
hours the viability of microbes was detected with an aqueous solution (2.5 mg/ml) of 3-[4,5-
dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT) (Sigma, St Louis, MO, USA) 
containing 0.1% Triton X-100 (Sigma). The plates were dipped into the MTT solution for 60 
seconds and dripped and dried for 30 seconds. The second incubation period lasted for 12 
hours under same conditions. At the end of the experiment plates were washed with 70 % 
ethanol, dried at room temperature and photographed under white light (20 W). Direct 
bioautographic detection process was performed according to the principals described by Botz 
et al. (73) (74). 
 
b) Results and conclusions 
 
 Directly after the TLC development the layers were dried at room temperature for 2 
hours so the solvents could evaporate. Afterwards microbiologic detection was performed as 
described previously. The suitability of the two most commonly used test organisms Candida 
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albicans (ATCC 90028) and Saccharomyces cerevisiae (ATCC 9763) were tested. For the 
detection of AmB Candida albicans gave more sensitive detection results and also more 
distinct zones of inhibition were observed on an evenly blue/purple layer colour. The viability 
of the test fungus is a crucial point of direct bioautography. It is important that the fungus 
suspension is grown to the log phase. That the optimal time of growth of the cultures in 
Mueller–Hinton broth supplemented with 2 % glucose was after 16 hours of incubation. 
Figure 21. Comparison of the results of densitometry, UV visualization and direct 
bioautography of freshly prepared amphotericin B solutions 
 
Just as for the UV detection direct bioautography also has its optimal concentration 
range for the measurement of the components. Since the microbiologic measurement is more 
sensitive, as little as 25 ng of AmB per spot is optimal for the observation of the minor 
component (RF=0.31) (Figure 21.). At higher concentrations the spots cannot be 
differentiated partly because during dipping of the layers into the inoculated Mueller-Hinton 
broth access active ingredient is washed over the layer from the overloaded spots, in this way 
spoiling the microbiologic detection. At lower concentrations the minor component cannot be 
detected presumably because its amount is below its minimal detectable concentration. 
During our experiments we observed that microbiologic detection is conspicuously 
more sensitive than UV visualization where at least 50 ng of AmB is necessary (Figure 22.). 
The densitometer can detect as little as 4 ng of AmB, but peaks can be integrated when the 
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amount spotted is over than 25 ng of AmB. As for direct bioautography even 0.8 ng AmB is 
detectable, thus 0.8 μg/ml AmB solutions can accurately be measured. 
Figure 22. Detection limits of amphotericin B with three different methods 
 
 
 Since DMSO could influence the chromatographic separation and might exert 
antifungal effect at certain concentrations, we tested each parameter and came to the 
conclusion that neither the RF value and spot form, nor the fungal cell growth is influenced by 
the amount of DMSO used in our experiments. 
 Our aims were to separate and detect the microbiological activity of main and minor 
components in fresh and degraded AmB solutions which were used as nasal sprays in a 
clinical study. We had to face a complex analytical problem because TLC of polyenes is 
poorly documented, direct bioautography of amphotericin B has not been published before 
and degradation of the observed substance makes the separation and the microbiologic 
visualization troublesome. With the aid of our optimized eluent (Chloroform – Methanol – 
Borate buffer pH 8,3; 4:5:1) two components can be separated on silica gel layers in AmB 
samples. The observed components both have antifungal effect, but since the minor 
component is present only in small amount, it can be visualized only when higher sample 
concentrations are used. According to our experiments a mixture of degradation products are 
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produced during storage of AmB solutions (Figure 23.). The degradation does influence 
chromatographic behaviour but does not alter the antifungal effect strikingly. 
Figure 23. Direct bioautography of freshly prepared (Vetranal and Fungizone) and 
degraded samples of amphotericin B solutions detected with Candida albicans. 
 
 It can be stated that direct bioautography proved to be a sensitive method with the 
detection limit of 0.8 ng/spot. Both with Vetranal and Fungizone samples same result were 
produced in the observed concentration range (0.5-1000.0 ng/spot) in case of TLC separation 
and also with microbiologic detection with C. albicans. We believe that with the above 
described method the examination of clinical study test samples will be complemented with 
information regarding the amount and activity of degradation products. In our judgment direct 
bioautographic detection method can be useful for future measurements since apart from 
being sensitive for a commonly used polyene antifungal of clinical practice, it is relatively 
fast, cheap and easy to perform. 
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F. Conclusions for the analysis and stability testing of amphotericin B 
preparations 
 
As described in the second part of my thesis, finding the most suitable analytical 
method for the measurement of AmB is a difficult task. The combined application of 
biological and chemical methods enables us to document the concentration and activity 
changes in AmB samples most precisely. With the aid of an accurate HPLC analysis and a 
sensitive bioassay, reliable information can be gathered during a future stability test. 
Further improvement of our methods would be the elaboration of a more sensitive 
HPTLC separation followed by direct bioautographic detection. It is very likely, that 
quantitative measurements can be achieved if the method is further improved based on the 
previous experience gained during the described bioassay measurements. 
In case a new stability test would be required, it would definitely be beneficial to 
document colloidal changes in the solutions also. This would contribute to the better 
understanding of physico-chemical changes occurring in water based solutions and also might 
give answers to the puzzling phenomena of temporary increase of antifungal activity. 
The questions razed and the problems solved during my analytical work all originated 
from a practical pharmaceutical task. Apart from the fact, that I had the chance to get 
acquainted with a variety of useful methods, the complexity of the analysis of polyenes is 
summarized in a way that might also be beneficial to other researchers in the fields of 
analytical sciences. 
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VI. Final general summary 
 
 Various topics from different fields of pharmaceutical sciences have been discussed in 
the thesis. Certainly a drawback of such diversity can be that no single project was specified 
in full detail, on the other hand, as an advantage, the thesis introduced a pharmaceutical 
approach which evolved during my work and my personal professional ideology. 
 Earlier clinical studies regarding the efficacy of antifungal treatment for chronic 
rhinosinusitis were summarized and evaluated. Emphasis was laid on pharmaceutically 
important factors such as stability, compliance and study design. Despite the heterogeneity of 
the published papers with contradictory results it was concluded, that chronic rhinosinusitis 
with nasal polyposis has an unclarified pathogenesis and the effectiveness of local antifungal 
therapy is far from clear. Nasal sprays were considered to be the most suitable form of drug 
delivery most importantly because of the convenience for patients, thus improving the 
adherence rate. Spray solutions were prepared under aseptic conditions by the hospital 
pharmacy. Glucose was omitted from the solutions because of the assumption that it might 
facilitate the growth of fungi. Patient adherence was relatively good. Even though a moderate 
decline was seen from month to month, at the end of the study the overall adherence was 
notably above the most commonly documented cut-off point for adherence of 80 %. The most 
common barrier to adherence was motivational. The incidence and also the regularity of side-
effects were higher in the AmB group than in the placebo group. 
 For the evaluation of long-term efficacy of amphotericin B treatment, a prospective 
randomized placebo controlled trial was conducted, involving 33 patients. Patients with nasal 
polyposis were operated on with an endoscopic technique and were treated with a nasal spray 
containing 5 mg/ml amphotericin B, while the placebo group received a nasal spray lacking 
amphotericin B. We evaluated our results with the aid of a modified Lund-Mackay CT score, 
the SNAQ-11 test, a quality of life test and endoscopy. Our results lead to the conclusion that 
the administration of amphotericin B nasal spray to patients operated on for nasal polyposis 
does not give rise to a significant alteration in either CT score, clinical symptoms, or quality 
of life. 
 The second part of the thesis summarizes and compares chemical (spectrophotometry, 
HPLC) and microbiological (bioassay, direct bioautography) methods for the quantitative 
measurement of amphotericin B. Optimized HPLC, TLC, bioassay and direct bioautography 
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methods were developed for the qualitative and quantitative measurement of amphotericin B. 
Several important observations were made regarding these optimized techniques. The stability 
test of amphotericin B nasal spray solutions was performed. The two detection methods 
applied (spectrophotometry and bioassay) showed strikingly different results. According to 
the chemical analysis the samples are considered relatively stable under all observed 
conditions, while bioassay showed complete loss of antifungal activity after 35 days of 
storage at room temperature and notable decrease was be observed at 4°C. We estimated the 
shelf life of the glucose-free solutions, being stored at 4°C, to be 30 days in accordance with 
our bioassay results. With the aid of our improved HPLC method several minor components 
can be detected in AmB samples. Earlier TLC methods for amphotericin B were tested and a 
new eluent system was documented. Although this TLC method in itself is not the most 
suitable method for the qualitative analysis of degradation products in AmB solutions, but it 
can indeed be a useful marker of degradation. Direct bioautography further improved the 
sensitivity of the method. Because the bioassay parameters recommended by the Ph. Eur. 6. 
were less sensitive and were only applicable for the measurement of a narrow concentration 
range, an optimized method was improved capable of the quantitative measurement of 
amphotericin B at the concentration range of 1,54-60,0 μg/ml. 
 All these observations contribute to the better – although still debatable – 
understanding of the role of local antifungal therapy in chronic rhinosinusitis and certainly the 
summarization and improvement of analytical methods will be highly beneficial for future 
clinical studies.  
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IX. Appendix 
A. Number of organisms recovered from patients with CR (N=210) and 
percentage of patients colonized with the species 
 Acremonium    5  (2.4%) 
 Alternaria   93  (44.3%) 
 Arachniotus citrinus  3  (1.4%) 
 Arthrographis kalrae   1 (0.5%) 
 Aspergillus   62 (29.5%) 
  A flavus  8 
  A fumigatus  17 
  A glaucus   6 
  A nidulans  1 
  A niger   5 
  A terreus   2 
  A versicolor   15 
  A versiforme   1 
  Aspergillus species* 7 
 Aureobasidium   8  (3.8%) 
 Beauveria    2  (1.0%) 
 Bipolaris    2  (1.0%) 
 Candida    45  (21.4%) 
  C albicans   31 
  C krusei   1 
  C lipolytica   1 
  C lusitaniae   1 
  C parapsilosis   9 
  C tropicalis   1 
  Candida species.*  1 
 Chaetomium    3  (1.4%) 
 Chryosporium    2  (1.0%) 
 Cladosporium    82  (39.0%) 
 Cryptococcus    4  (1.9%) 
  C albidus   1 
  C laurentii   2 
  Cryptococcus species*  1 
 Curvularia    2  (1.0%) 
 Epicoccum    12  (5.7%) 
 Exophiala jeanselmei   2  (1.0%) 
 Fusarium    34  (16.2%) 
 Geotrichum    10  (4.8%) 
 Gliomastix    1  (0.5%) 
 Monilia    3  (1.4%) 
 Mucor     4  (1.9%) 
 Nigrospora    1  (0.5%) 
 Oidiodendron    1  (0.5%) 
 Paecilomyces    5  (2.4%) 
 Papularia    4  (1.9%) 
 Penicillium    91  (43.3%) 
 Phoma     2  (1.0%) 
 Pithomyces    14  (6.7%) 
 Pseudallescheria boydii 1  (0.5%) 
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 Rhinocladiella    3  (1.4%) 
 Rhizopus    5  (2.4%) 
 Rhodotorula    4  (1.9%) 
  R minuta   2  
  Rhodotorula species*  2 
 Saccharomyces cerevisiae  1  (0.5%) 
 Sagrahamala    1  (0.5%) 
 Scolecobasidium   1  (0.5%) 
 Scopulariopsis    3  (1.4%) 
  S brumptii   1 
  Scopulariopsis species* 2 
 Trichoderma    8  (3.8%) 
 Trichophyton    2  (1.0%) 
  T rubrum   1 
  Trichophyton species*  1 
 Trichosporon beigelii   1  (0.5%) 
 Ustilago    13  (6.2%) 
Total No. of organisms    541 
*subclasses not available 
(from The Diagnosis and Incidence of Allergic Fungal Sinusitis, J. U. Ponikau et al in Mayo Clin 
Proc. 1999;74:877-884) 
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B. Scoring systems of outcome parameters for the clinical study 
1. Modified Lund–Mackay CT evaluation score system 
Scoring 
0 = Not opacified 
1 = Less than 1/3 opacified 
2 = Between 1/3 and 2/3 opacified 
3 = More than 2/3 opacified, but still air-containing 
4 = Complete opacification (no air) 
Maximum score : 5x4x2=40 
Each side was separately evaluated for opacification of the 
maxillary, anterior and posterior ethmoideal, sphenoidal and 
frontal sinus. 
 
2. SNAQ-11 questionnaire relating to sinus symptoms questions 
Nasal obstruction 
Feeling of nasal fullness, sneezing 
Facial pain, pressure feeling 
Anterior nasal discharge 
Posterior nasal discharge 
Sneezing 
Cough 
Diminished smell 
Headache 
Ear pain, pressure feeling in the ear 
Sleeping difficulties, daytime sleepiness 
 
Evaluation 
0 = No symptom 
1 = Very mild symptom 
2 = Mild symptom 
3 = Moderate symptom 
4 = Serious symptom 
5 = Extremely serious symptom 
 
Scores to questions 1 and 2 should be multiplied by 3, and to 
question 3 by 2; the maximum available score is 80. 
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3. Quality of life evaluation score system 
Subjective evaluation on 7-point scale. 
(0: not troubled by nasal symptoms 6: extremely troubled by 
nasal symptoms) 
Questions 
 
Regular activities at home and at work? 
Recreational activities? 
Tiredness and/or fatigue? 
Sleep? 
Thirst? 
Feeling irritable? 
 
Maximum score: 36 points 
 
C. Questions of the modified brief medication questionnaire for patients 
using amphotericin B nasal sprays. 
Type of screens and questions 
A.  Regimen screen 
A1.  On how many days did you use the spray? 
A2.  How many times per day did you use it? 
A3.  How many doses did you apply each time? 
A4.  How many times did you miss using the spray? 
B.  Belief Screen 
B1.  How does this medicine work for you? 
B2.  Does the medication bother you in any way? 
C.  Recall Screen 
C1.  Did you ever forget to use the spray? 
C2.  Was it troublesome for you to use the spray twice a day? 
C3.  Do you feel, that you take so many medications that it is difficult for 
you to comply with the instructions? 
D.  Access Screen 
D1.  Did you have problems with getting the refills in time? 
D2.  Has it ever happened, that you ran out of spray solution earlier than 
the next visit due? 
D3.  Did the sprays work properly? 
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D. Comparative demonstration of agardiffusion and direct bioautographic 
measurements 
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E. Composition of the examined media for the bioassay of amphotericin B 
 
Assay medium Code Composition 
University of Pécs 
Bioassay Medium 
MHA-E 
Na2HPO4x10H2O
1 
4,0 g 
NaCl
2 
5,0 g 
Lab-Lemco
3 
5,0 g 
Peptone (pepsin digested meat)
1 
10,0 g 
Agar
4 
20,0 g 
Distilled water
 
1000 ml 
Modified Antibiotic 
Medium 12 [4] 
MAM-12 
Yeast extract
1 
7,0 g 
Peptone (pepsin digested meat)
1 
7,0 g 
Glucose
2 
15,0 g 
Agar
4 
20,0 g 
Distilled water 1000 ml 
Mueller Hinton Agar MHA 
Bio Rad MHA 84888
5
 35,0 g 
Distilled water 1000 ml 
Mueller Hinton Agar 
supplemented with 2% 
glucose and 0,5 µg/ml 
methylene blue [5, 6] 
MHA-GMB 
Bio Rad MHA 84888
5
 35,0 g 
Glucose
2 
20,0 g 
Methylene blue
 
0,5 mg 
Distilled water 1000 ml 
Ph. Eur. 6. medium F 
[7] 
F-M 
Peptone (pepsin digested meat)
1
 9,4 g 
Yeast extract
1 
4,7 g 
Lab Lemco
3 
2,4 g 
NaCl
2 
10,0 g 
Glucose
2 
10,0 g 
Agar
4 
20,0 g 
Distilled water 1000 ml 
1
 Reanal, Budapest, Hungary; 
2
 Hungaropharma, Budapest, Hungary; 
3
 Oxoid Ltd, 
Cambridge, UK; 
4
 Merck, Darmstadt, Germany; 
5
 Bio-Rad, Hercules, USA 
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